Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1996 2
1997 3
1998 1
2002 1
2004 2
2005 1
2006 3
2007 4
2008 1
2009 3
2010 1
2011 4
2012 3
2015 2
2016 2
2017 4
2018 3
2019 8
2020 8
2021 13
2022 4
2023 6
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Dagnew AF, et al. Among authors: schuind a. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. Lancet Infect Dis. 2019. PMID: 31399377 Clinical Trial.
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination.
Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A; Zoster-049 Study Group. Strezova A, et al. Open Forum Infect Dis. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36299530 Free PMC article.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, Choo EJ, Curiac D, Di Paolo E, Dionne M, Eckermann T, Esen M, Ferguson M, Ghesquiere W, Hwang SJ, Avelino-Silva TJ, Kosina P, Liu CS, Markkula J, Moeckesch B, Murta de Oliveira C, Park DW, Pauksens K, Pirrotta P, Plassmann G, Pretswell C, Rombo L, Salaun B, Sanmartin Berglund J, Schenkenberger I, Schwarz T, Shi M, Ukkonen B, Zahaf T, Zerbini C, Schuind A, Cunningham AL; Zoster-049 Study Group. Boutry C, et al. Among authors: schuind a. Clin Infect Dis. 2022 Apr 28;74(8):1459-1467. doi: 10.1093/cid/ciab629. Clin Infect Dis. 2022. PMID: 34283213 Free PMC article. Clinical Trial.
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer.
Giacomini A, Turati M, Grillo E, Rezzola S, Ghedini GC, Schuind AC, Foglio E, Maccarinelli F, Faletti J, Filiberti S, Chambery A, Valletta M, Melocchi L, Gofflot S, Chiavarina B, Turtoi A, Presta M, Ronca R. Giacomini A, et al. Among authors: schuind ac. Exp Hematol Oncol. 2023 Sep 25;12(1):82. doi: 10.1186/s40164-023-00441-y. Exp Hematol Oncol. 2023. PMID: 37749607 Free PMC article.
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, Tavares Da Silva F, Rappuoli R, Garçon N, Innis BL. Cohet C, et al. Among authors: schuind a. Vaccine. 2019 May 21;37(23):3006-3021. doi: 10.1016/j.vaccine.2019.04.048. Epub 2019 Apr 25. Vaccine. 2019. PMID: 31031030 Free article. Review.
State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop.
Schuind AE, Rees H, Schiller J, Mugo N, Dull P, Barnabas R, Clifford GM, Liu G, Madhi SA, Morse RB, Moscicki AB, Palefsky JM, Plotkin S, Sierra MS, Slifka MK, Vorsters A, Kreimer AR, Didierlaurent AM. Schuind AE, et al. Prev Med Rep. 2023 Jul 19;35:102331. doi: 10.1016/j.pmedr.2023.102331. eCollection 2023 Oct. Prev Med Rep. 2023. PMID: 37576844 Free PMC article. Review.
Evidence for an HPV one-dose schedule.
Stanley M, Schuind A, Muralidharan KK, Guillaume D, Willens V, Borda H, Jurgensmeyer M, Limaye R. Stanley M, et al. Among authors: schuind a. Vaccine. 2024 Jul 11;42 Suppl 2:S16-S21. doi: 10.1016/j.vaccine.2024.01.046. Epub 2024 Nov 7. Vaccine. 2024. PMID: 39521566 Free article. Review.
80 results